Related Experiment Video
Updated: Jun 15, 2025
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian
George Au-Yeung1,2, Emily MacArthur3, Joanna Chan1
1Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Abstract:
In the field of gynecologic cancer, low-grade serous ovarian cancer (LGSOC) has been poorly understood and underinvestigated until recently. Similarly, understanding of the distinct properties and therapeutic sensitivities of gynecologic melanoma and cervical neuroendocrine tumors has recently accelerated. For each of these rare cancers, we explore the epidemiology and natural history, discuss the prognosis, diagnostic testing, and contemporary molecular classification, and then deliberate existing and emerging therapeutic strategies. In LGSOC, we focus on the clinical relevance of recent molecular studies that shed light on the importance of mitogen-activated protein kinase (MAPK) pathway gene mutation and chromosome 1 copy-number change on prognosis and MEK inhibitor sensitivity. We also discuss the relative chemoresistance of this disease and the fact that attention is shifting to combinations of molecular therapies such as endocrine agents plus cyclin-dependent kinase 4/6 inhibitors or MEK inhibitors plus FAK inhibitors. Gynecologic tract melanomas harbor a lower frequency of canonical BRAF mutations, and have lower tumor mutational burden and immune cell infiltration than cutaneous melanomas (CMs). As a result, patients with this disease are less likely to respond to BRAF/MEK or immune checkpoint inhibition than patients with CM. Emerging strategies include the combination of antiangiogenic agents with immune checkpoint inhibitors and the use of adoptive cellular therapies. In cervical neuroendocrine cancer, we discuss the use of surgery in early-stage disease, and the uncertainties regarding the role of radiotherapy. We also explore the evidence for chemotherapy and emerging investigational strategies including the use of poly (ADP-ribose) polymerase inhibitors. For all situations, we explore the shared decision-making process with the patient.
Insights
Recent advances improve understanding of rare gynecologic cancers like low-grade serous ovarian cancer (LGSOC), gynecologic melanoma, and cervical neuroendocrine tumors. Research highlights molecular targets and novel therapies, shifting focus to personalized treatment strategies for better patient outcomes.
Area of Science:
- Gynecologic Oncology
- Rare Cancers
- Molecular Pathology
Background:
- Low-grade serous ovarian cancer (LGSOC), gynecologic melanoma, and cervical neuroendocrine tumors are rare gynecologic malignancies with historically limited understanding.
- Recent research has accelerated insights into their distinct biological properties, epidemiology, and therapeutic sensitivities.
- These advancements necessitate a review of current knowledge and emerging treatment paradigms.
Purpose of the Study:
- To explore the epidemiology, natural history, prognosis, diagnostics, and molecular classifications of LGSOC, gynecologic melanoma, and cervical neuroendocrine tumors.
- To deliberate existing and novel therapeutic strategies, including molecularly targeted therapies and immunotherapies.
- To synthesize current evidence and guide clinical decision-making for these rare gynecologic cancers.
Main Methods:
- Review of recent molecular studies, focusing on gene mutations (e.g., MAPK pathway in LGSOC) and copy-number changes.
- Analysis of epidemiological data, tumor characteristics (mutational burden, immune infiltration), and treatment outcomes for gynecologic melanomas compared to cutaneous melanomas.
- Evaluation of therapeutic strategies for cervical neuroendocrine tumors, including surgery, radiotherapy, chemotherapy, and novel agents like PARP inhibitors.
Main Results:
- LGSOC shows prognostic relevance of MAPK pathway mutations and chromosome 1 copy-number changes, influencing MEK inhibitor sensitivity and highlighting chemoresistance.
- Gynecologic melanomas exhibit lower BRAF mutation frequency and immune infiltration than cutaneous melanomas, suggesting reduced response to BRAF/MEK or checkpoint inhibitors.
- Emerging strategies for LGSOC involve endocrine agents, CDK4/6 inhibitors, MEK inhibitors, and FAK inhibitors; for melanoma, combinations of antiangiogenic and immune checkpoint inhibitors, and adoptive cell therapies are explored; for neuroendocrine tumors, PARP inhibitors are under investigation.
Conclusions:
- Personalized therapeutic strategies combining molecularly targeted agents and immunotherapies are crucial for improving outcomes in rare gynecologic cancers.
- Understanding the unique molecular profiles of LGSOC, gynecologic melanoma, and cervical neuroendocrine tumors is key to developing effective treatments.
- Shared decision-making with patients is essential when navigating complex treatment options for these rare malignancies.
